Replies to post #1996 on InspireMD Inc (NSPR)

[tomsen]

Only 8.51% of this company is owned by institutions. I haven't bothered to look and I am not going to, but I would bet that the board, directors, and employees of this company own more than that and there is at least 10 million shares set aside for incentives. That is why this company is a cash cow to management. The only way they will sell this company is if they were offered at least 100 million and that would translate into about $2.50 a share. Not going to happen. The board and directors really do control this company not the shareholder. So if you argue that has to be voted on-yeah your right- but, they control the vote. They either own or have that much influence in the voting process. Right now you can't beat them.

[RamiroGaliza]

Regarding current product and pipeline, NSPR does have great product, patents and promising pipeline. Currently in the market there are CGuard (carotid) and MGuard (coronary), and they are searching for partner to develope new generation MGuard DES. Furthermore, their pipeline includes next generation CGuard (carotid), NGuard (neuro) and PVGuard (peripheral). Current sales aren't that huge only because they are just starting to develop their commercial paths and still not approved in USA and many other markets (but on straight track for it). Every little time we see new approvals for CGuard (Mexico, Australia, etc...).